Indications

Inmit is indicated for the treatment of nausea and vomiting of pregnancy in women who have not responded to conservative management.

Pharmacology

Inmit is a combination product containing:

• Doxylamine Succinate: An antihistamine that blocks histamine (H1​ ) receptors in the brain. It also affects the vestibular system and muscarinic receptors, which decreases the stimulation of the vomiting center.
• Pyridoxine Hydrochloride (Vitamin $B$$6$​): This is a vitamin B6​ analog with antiemetic properties that help to prevent nausea and vomiting.

Dosage & Administration

• Initial Dose (Day 1): Take one tablet orally at bedtime.
• If symptoms persist (Day 2): Increase the dose to one tablet in the morning and one tablet at bedtime.
• Maximum Recommended Dose: Two tablets per day (one in the morning, one at bedtime). The tablets should be swallowed whole with water on an empty stomach. They should not be crushed, chewed, or split. The medication should be taken daily, not on an as-needed basis.

Interaction

• Monoamine Oxidase Inhibitors (MAOIs): The use of Inmit is contraindicated in women taking MAOIs, as MAOIs can prolong and intensify the central nervous system side effects of antihistamines.
• Alcohol and other CNS depressants: Concurrent use is not recommended as it may increase the sedative effects.

Contraindications

Inmit is contraindicated in women with:

• Known hypersensitivity to Doxylamine Succinate, other ethanolamine derivative antihistamines, Pyridoxine Hydrochloride, or any of the inactive ingredients.
• Concurrent use of monoamine oxidase (MAO) inhibitors.

Side Effects

The most common side effect is somnolence (sleepiness). Other side effects may result from the combined use of Inmit with CNS depressants.

Pregnancy & Lactation

This is a Pregnancy Category A drug and is specifically for the treatment of nausea and vomiting of pregnancy. Both doxylamine succinate and pyridoxine hydrochloride are excreted into breast milk, so caution should be exercised while breastfeeding.

Precautions & Warnings

• Somnolence: Inmit may cause somnolence. Women should avoid activities requiring mental alertness, such as driving or operating heavy machinery.
• CNS Depressants: Use is not recommended with alcohol or other central nervous system depressants.
• Anticholinergic Properties: Due to the anticholinergic properties of doxylamine succinate, Inmit should be used with caution in women with conditions such as asthma, increased intraocular pressure, narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, or urinary bladder-neck obstruction.

Overdose Effects

Since Inmit is an extended-release formulation, the signs and symptoms of an overdose may not appear immediately. Overdose symptoms may include restlessness, dry mouth, dilated pupils, sleepiness, vertigo, confusion, and a rapid heart rate (tachycardia). At toxic doses, doxylamine succinate can cause seizures, rhabdomyolysis, and acute renal failure. Treatment for an overdose typically involves gastric lavage, activated charcoal, whole bowel irrigation, and symptomatic care.

Therapeutic Class

Inmit belongs to the therapeutic class of anti-emetic drugs.

Storage Conditions

Store below 30°C in a dry place, protected from light. Keep out of the reach of children.